Market Place
Sourcing Support
AstraZeneca Pharma India surrenders Olaparib marketing authorizat
16 Apr 2025 //
INDPHARMAPOST
LYNPARZA Demonstrates Prolonged Survival in Early Breast Cancer
11 Dec 2024 //
BUSINESSWIRE
Merck Announces Ph 3 KEYLYNK-001 Trial Success in Ovarian Cancer
09 Dec 2024 //
BUSINESSWIRE
AstraZeneca gets nod for sale, distribution of cancer drug Lynparza
27 Nov 2024 //
BUSINESS STD
AstraZeneca Pharma shares up on CDSCO nod for cancer drug Lynparza
27 Nov 2024 //
BUSINESS STD
FDA Approves FoundationOne CDx as Companion Diagnostics for Lynparza
03 Sep 2024 //
BUSINESSWIRE
Voluntary Announcement Olaparib Tablets Obtains Drug Registration Approval
03 Jun 2024 //
PRESS RELEASE
Tango Stops Early Cancer Trial Liver Toxicity, Drops Out of Race Against Roche
23 May 2024 //
BIOSPACE
Regulator asks state bodies to limit scope of key cancer drug
23 May 2024 //
ECONOMICTIMES
DCGI orders withdrawal of cancer drug Olaparib for certain treatments
23 May 2024 //
ECONOMICTIMES
AACR: Detailed data spark hope for Merck combo in NSCLC
09 Apr 2024 //
FIERCE PHARMA
Merck Provides Update on Ph 3 KEYLYNK-006 Trial for Certain Patients With NSCLC
21 Mar 2024 //
BUSINESSWIRE
AstraZeneca Shows Lynparza Combo Could Address Unmet Endometrial Cancer Need
19 Mar 2024 //
BIOSPACE
Zydus launches anti-cancer generic drug olaparib in India
13 Mar 2024 //
ECONOMIC TIMES
Merck halts trial after Keytruda-Lynparza combo flunks PhIII study in lung cancer
08 Dec 2023 //
BUSINESSWIRE
IMFINZI plus LYNPARZA reduced the risk of death by 45% in endometrial cancer
21 Oct 2023 //
BUSINESSWIRE
LYNPARZA Plus Abiraterone and Prednisone or Prednisolone Approved in Japan
24 Aug 2023 //
BUSINESSWIRE
Health Canada approves Lynparza with abiraterone for patients with BRCA mCRPC
14 Jul 2023 //
BIOSPACE
Olaparib Bolsters Lutetium Lu 177 Vipivotide Tetraxetan Activity in mCRPC
11 Jul 2023 //
ONCLIVE
LYNPARZA & IMFINZI combination reduced risk of death in advanced ovarian cancer
03 Jun 2023 //
BUSINESSWIRE
AZ, Merck`s Lynparza wins new use in prostate cancer subgroup
02 Jun 2023 //
FIERCE PHARMA
LYNPARZA® (olaparib) plus abiraterone approved in the US
01 Jun 2023 //
BUSINESSWIRE
FDA clears Lynparza combo for BRCA-mutated prostate cancer
01 Jun 2023 //
FDA
AstraZeneca reports positive results from endometrial cancer therapy trial
30 May 2023 //
CLINICAL TRIALS ARENA
Imfinzi plus Lynparza and Imfinzi alone both improved progression-free survival in advanced endometrial cancer
26 May 2023 //
PRESS RELEASE
Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression
26 May 2023 //
ENDPTS
US FDA panel backs restricted use of AstraZeneca`s prostate cancer drug
02 May 2023 //
BUSINESS-STANDARD
FDA panel gives Lynparza narrow backing in prostate cancer
29 Apr 2023 //
FIERCE PHARMA
Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib)
28 Apr 2023 //
BUSINESSWIRE
FDA raises concerns about plan to expand Lynparza`s use in prostate cancer
27 Apr 2023 //
ENDPTS
Junshi`s Lynparza rival hits mark in ovarian cancer phase 3
13 Apr 2023 //
FIERCE BIOTECH
NICE’s recommendation on Lynparza labelled ‘an amazing moment’
07 Apr 2023 //
THE PHARMA LETTER
AZ`s Imfinzi-Lynparza will face tough FDA scrutiny: analyst
06 Apr 2023 //
FIERCE PHARMA
MHRA approves prostate cancer combination therapy
21 Mar 2023 //
EUROPEAN PHARMACEUTICAL REVIEW
AstraZeneca and MSD’s Lynparza gets green light
20 Mar 2023 //
PHARMATIMES
U.S. FDA panel to review expanded use of Merck-AstraZeneca`s cancer drug
03 Mar 2023 //
REUTERS
Lynparza`s final OS results come up short in PROpel study
17 Feb 2023 //
PRESS RELEASE
Natco Pharma submits application with USFDA for generic cancer drug
13 Feb 2023 //
ECONOMIC TIMES
Europe broadens Lynparza use as FDA ups scrutiny of PARP drugs
22 Dec 2022 //
BIOPHARMADIVE
LYNPARZA With Abiraterone and Prednisone Approved in the EU for mCRPC
21 Dec 2022 //
PRESS RELEASE
FDA delays review on AZ and Merck`s Lynparza in prostate cancer
16 Dec 2022 //
FIERCEPHARMA
AZ, Merck tap sports to spark prostate cancer conversations
14 Dec 2022 //
FIERCEPHARMA
FDA Confirms Paragraph IV Patent Litigation for Olaparib Tablets
14 Dec 2022 //
FDA
AZ, MSD’s Lynparza in combo with abiraterone recommends for approval in EU
15 Nov 2022 //
PHARMABIZ
AstraZeneca, Merck cull one Lynparza indication in ovarian cancer patients
24 Sep 2022 //
ENDPTS
LYNPARZA Approved in China as Treatment With Bevacizumab for HRD
22 Sep 2022 //
BUSINESSWIRE
LYNPARZA in Combination with Bevacizumab Demonstrates Benefit in Ovarian Cancer
09 Sep 2022 //
BUSINESSWIRE
MHRA grants marketing authorisation for olaparib to treat breast cancer
08 Sep 2022 //
PHARMACEUTICAL-TECHNOLOGY
AstraZeneca, Merck`s Lynparza rejected by NICE in prostate cancer over pricing
08 Sep 2022 //
FIERCEPHARMA
AstraZeneca Scores Japanese Approvals in NSCLC, gMG and Breast Cancer
26 Aug 2022 //
BIOSPACE
Myriad Receives Expanded Coverage in Japan for Use of BRACAnalysis Diagnostic
25 Aug 2022 //
GLOBENEWSWIRE
AstraZeneca India receives DCGI`s nod to market drug treating breast cancer
20 Aug 2022 //
HEALTH ET
Lynparza combo accepted by FDA for priority review
17 Aug 2022 //
THEPHARMALETTER
Amarin suspends German sales force as Vascepa`s European launch sputters
05 Aug 2022 //
FIERCEPHARMA
Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program
01 Aug 2022 //
BUSINESSWIRE
Merck, AstraZeneca Partnered Lynparza Fails Late-Stage Colorectal Cancer Trial
20 Jul 2022 //
BENZINGA
LYNPARZA Receives Positive Opinion From EU CHMP for Early Breast Cancer
27 Jun 2022 //
BUSINESSWIRE
Improved outcome for prostate cancer patients in Phase III PROpel trial
22 Jun 2022 //
EUROPEANPHARMACEUTICALREVIEW
Results From PIII PROpel Trial of LYNPARZA Plus Abiraterone in 1L mcrPC
21 Jun 2022 //
BUSINESSWIRE
LYNPARZA reduced risk of death by 32% in treatment of BRCA-mutated breast cancer
16 Mar 2022 //
BUSINESSWIRE
